You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國抗體-B(03681.HK)中期虧損擴大至1.44億元
格隆匯 08-22 21:58

格隆匯8月22日丨中國抗體-B(03681.HK)發佈公吿,截至2022年6月30日止六個月,公司其他收入及收益790.3萬元人民幣,同比減少37.99%;期內虧損由截至2021年6月30日止6個月的人民幣1.14億元,增加人民幣2940萬元至截至2022年6月30日止6個月的人民幣1.44億元,主要由於(i)匯兑虧損淨額增加約人民幣3190萬元。

於報吿期內,公司的大部分現金及現金等價物以人民幣計值。大部分匯兑虧損乃因香港總部的功能貨幣為港元與集團的呈列貨幣為人民幣間的差異而產生,該費用並不代表公司的實際虧損;(ii)銀行利息收入減少約人民幣430萬元;及被(iii)完成Suciraslimab治療RA的III期入組導致報吿期內研究與開發商務拓展成本減少約人民幣790萬元所抵銷。

董事已議決不會就報吿期宣派中期股息。

公司的旗艦產品SM03(Suciraslimab),(抗CD-22單抗)—治療類風濕關節炎("RA")的III期臨牀試驗招募於2021年12月31日完成,達成招募530名受試者入組,超出招募510名受試者的預期目標。III期研究第24周主要臨牀終點的初步結果預計於2022年第三季度獲得,安全性及有效性第52周的最終研究結果預計於2023年第一季度讀出。

公司正在建設公司處於集團中國總部的商業生產基地—新蘇州基地,該基地位於中國蘇州獨墅湖高等教育區。第一期開發產能達6000升,預計於2024年初投入使用。連同公司現有於海口生產基地的1200升產能,公司的產能將高達每年二十萬個療程。於新蘇州基地竣工後,生產基地最大總產能將超過36,000升(高達每年一百萬個療程)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account